Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP396259.RAlZ6zpq-ATuqdovwdC3L1jSp9BXKD_wm0pewKkJia6eA130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP396259.RAlZ6zpq-ATuqdovwdC3L1jSp9BXKD_wm0pewKkJia6eA130_provenance.
• NP542004.RApBosatV9ZOFlFjaCROk9vhnSc0FOWar13PQiXfKEfC8130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP542004.RApBosatV9ZOFlFjaCROk9vhnSc0FOWar13PQiXfKEfC8130_provenance.
• NP724011.RABefA4z4nEVvXqqOU7qLIUTTm5YxOpJ521mYgZao4pBY130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP724011.RABefA4z4nEVvXqqOU7qLIUTTm5YxOpJ521mYgZao4pBY130_provenance.
• NP481205.RAmT-yJBtC1Ghqjpuxgn-6BwEFnkfl4k9_V5ceita9hiU130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP481205.RAmT-yJBtC1Ghqjpuxgn-6BwEFnkfl4k9_V5ceita9hiU130_provenance.
• NP260468.RAyiabb0x3aPGZ1rV-MXq5R8SQJI_ajj7TvaEpWobiPzY130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP260468.RAyiabb0x3aPGZ1rV-MXq5R8SQJI_ajj7TvaEpWobiPzY130_provenance.
• NP407154.RAa5973eVvn0bM5nhuBXeBp6iPKjx2B6k043hymLZtQuE130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP407154.RAa5973eVvn0bM5nhuBXeBp6iPKjx2B6k043hymLZtQuE130_provenance.
• NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_provenance.
• assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP679254.RABo-yGB7UYHcwSUwIoi7j8EN9TwUk-7otMHSAdN6kk-Q130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679254.RABo-yGB7UYHcwSUwIoi7j8EN9TwUk-7otMHSAdN6kk-Q130_provenance.
• NP679256.RADVpb88C6isyUasyYtLWWx8tnOXC3sobXkb_twsqb680130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679256.RADVpb88C6isyUasyYtLWWx8tnOXC3sobXkb_twsqb680130_provenance.
• NP679257.RADEPrmQ0OnX_npKgoe-ExIW7a5Cq3yYUZH18KJfkqkqc130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679257.RADEPrmQ0OnX_npKgoe-ExIW7a5Cq3yYUZH18KJfkqkqc130_provenance.
• NP407164.RAnVB-XeQNCYrFBxsgQDLyJB8chLVyDtVlUW82zMNb0vg130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP407164.RAnVB-XeQNCYrFBxsgQDLyJB8chLVyDtVlUW82zMNb0vg130_provenance.
• NP683766.RAvLwNfywfAWhz4t_U6HH7VkI1xZ5zoqtCtCntIrTVCSw130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP683766.RAvLwNfywfAWhz4t_U6HH7VkI1xZ5zoqtCtCntIrTVCSw130_provenance.
• NP683841.RAtxUPu_Z1HaIs3Zg7pwVwuYOVUQI05-acoeuqALz1r2c130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP683841.RAtxUPu_Z1HaIs3Zg7pwVwuYOVUQI05-acoeuqALz1r2c130_provenance.
• NP679253.RAp4SJj4fM1W7FqN5eOUfErAjtCPqpw62JaGcRmXnbM-g130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679253.RAp4SJj4fM1W7FqN5eOUfErAjtCPqpw62JaGcRmXnbM-g130_provenance.
• NP407290.RAEzvaXGD0n_XI52woN2Y2R1pkipr4UF2MO9YlVqNf_0M130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP407290.RAEzvaXGD0n_XI52woN2Y2R1pkipr4UF2MO9YlVqNf_0M130_provenance.
• NP683749.RAGgxFQXTzskdnan7UXNB-3jLKToK6UmbOQ8EUqGAoK9M130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP683749.RAGgxFQXTzskdnan7UXNB-3jLKToK6UmbOQ8EUqGAoK9M130_provenance.
• NP679261.RAG_ad3IKjcXTh9vQ0LtHHqKUf9gb_XS-iFGmeSULMzkA130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679261.RAG_ad3IKjcXTh9vQ0LtHHqKUf9gb_XS-iFGmeSULMzkA130_provenance.
• NP679255.RAyPFCMSc1S9L3qEdQaeLSZcFjr_luOfXarkZ_l5WfALI130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679255.RAyPFCMSc1S9L3qEdQaeLSZcFjr_luOfXarkZ_l5WfALI130_provenance.
• NP679259.RA-fVshuFbW5mYtag30e-CwsCP8L5bl5oF8guy6qzksIY130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679259.RA-fVshuFbW5mYtag30e-CwsCP8L5bl5oF8guy6qzksIY130_provenance.